Omeros (NASDAQ:OMER) Price Target Raised to $40.00 at HC Wainwright

Omeros (NASDAQ:OMER) had its price objective hoisted by HC Wainwright from $20.00 to $40.00 in a research report released on Thursday, Marketbeat Ratings reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

OMER has been the subject of a number of other reports. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Wednesday, October 15th. Wall Street Zen upgraded Omeros from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. D. Boral Capital reissued a “buy” rating and issued a $36.00 price objective on shares of Omeros in a report on Wednesday, December 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a research note on Wednesday, October 8th. Finally, WBB Securities reaffirmed a “strong-buy” rating and set a $45.00 price objective on shares of Omeros in a report on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $40.33.

Omeros Stock Down 4.5%

OMER opened at $13.45 on Thursday. Omeros has a twelve month low of $2.95 and a twelve month high of $17.65. The company’s 50-day moving average price is $10.48 and its two-hundred day moving average price is $6.57. The stock has a market cap of $953.61 million, a price-to-earnings ratio of -6.66 and a beta of 2.38.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.39. As a group, sell-side analysts anticipate that Omeros will post -3.09 earnings per share for the current year.

Hedge Funds Weigh In On Omeros

Large investors have recently modified their holdings of the company. Trexquant Investment LP purchased a new position in Omeros during the first quarter valued at approximately $88,000. Acadian Asset Management LLC purchased a new position in shares of Omeros during the 1st quarter valued at $357,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in shares of Omeros by 35.0% during the 2nd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 40,500 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 10,500 shares in the last quarter. Cypress Capital Group increased its holdings in shares of Omeros by 20.7% in the second quarter. Cypress Capital Group now owns 42,000 shares of the biopharmaceutical company’s stock worth $126,000 after purchasing an additional 7,200 shares during the period. Finally, Harbour Investments Inc. raised its position in shares of Omeros by 46.1% in the second quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 4,251 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors.

Key Omeros News

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: HC Wainwright raised its price target for OMER to $40 (from $20) and carries a Buy rating, signaling analysts see substantial upside versus current levels. This upgrade can support bullish sentiment and buying interest. HC Wainwright raises OMER PT to $40
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating and set a $36 price target, another analyst vote of confidence that could attract momentum buyers. D. Boral reaffirms Buy on OMER
• Positive Sentiment: Omeros showed a post-close/after-hours move higher in recent trading, indicating intraday volatility and that some investors are reacting positively to recent news flows. After-hours strength can sometimes precede renewed buying next session. After-hours move coverage
• Neutral Sentiment: Needham maintained a Hold rating (balanced risk/reward view and gradual ramp for Yartemlea), which tempers the bullish analyst actions and adds a cautious voice to the analyst mix. Needham Hold note
• Neutral Sentiment: Omeros released details on FDA approval and commercialization plans for YARTEMLEA; investors are parsing launch timelines, distribution, and payer strategy — important for revenue visibility but not an immediate binary outcome. FDA approval/commercialization transcript
• Neutral Sentiment: Omeros announced Yartemlea will be priced at $36,000 per single-dose vial. While the price point supports revenue per dose, it also raises potential payer/access questions that could delay uptake — making near-term commercial performance uncertain. Pricing announcement

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.